OTCPK:KWBT

Stock Analysis Report

Executive Summary

Kiwa Bio-Tech Products Group Corporation, through its subsidiaries, develops, manufactures, markets, and distributes bio-technological products for the agricultural market primarily in the People’s Republic of China.

Snowflake

Fundamentals

Adequate balance sheet and overvalued.


Similar Companies

Share Price & News

How has Kiwa Bio-Tech Products Group's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-3.2%

KWBT

2.0%

US Biotechs

1.0%

US Market


1 Year Return

-55.9%

KWBT

-5.5%

US Biotechs

8.0%

US Market

Return vs Industry: KWBT underperformed the US Biotechs industry which returned -5.5% over the past year.

Return vs Market: KWBT underperformed the US Market which returned 8% over the past year.


Shareholder returns

KWBTIndustryMarket
7 Day-3.2%2.0%1.0%
30 Day-72.0%-2.2%-0.07%
90 Day-81.3%-2.0%-1.0%
1 Year-55.9%-55.9%-4.6%-5.5%10.4%8.0%
3 Year-88.0%-88.0%15.4%11.4%46.2%36.7%
5 Year-25.0%-25.0%-3.1%-7.8%64.3%46.2%

Price Volatility Vs. Market

How volatile is Kiwa Bio-Tech Products Group's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Kiwa Bio-Tech Products Group undervalued compared to its fair value and its price relative to the market?

0.22x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate KWBT's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate KWBT's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: KWBT is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: KWBT is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate KWBT's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: KWBT is good value based on its PB Ratio (0.2x) compared to the US Biotechs industry average (2.6x).


Next Steps

Future Growth

How is Kiwa Bio-Tech Products Group forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

42.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: KWBT is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: KWBT is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: KWBT is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if KWBT's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if KWBT's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if KWBT's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Kiwa Bio-Tech Products Group performed over the past 5 years?

9.2%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: KWBT is unprofitable, but has reduced losses over the past 5 years at a rate of 9.2% per year.

Accelerating Growth: Unable to compare KWBT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: KWBT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (83.4%).


Return on Equity

High ROE: KWBT has a negative Return on Equity (-7.09%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: KWBT is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: KWBT is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Kiwa Bio-Tech Products Group's financial position?


Financial Position Analysis

Short Term Liabilities: KWBT's short term assets ($31.4M) exceeds its short term liabilities ($19.1M)

Long Term Liabilities: KWBT has no long term liabilities


Debt to Equity History and Analysis

Debt Level: KWBT's debt to equity ratio (14.9%) is considered satisfactory

Reducing Debt: KWBT had negative shareholder equity 5 years ago, but is now positive and has therefore improved.

Debt Coverage: KWBT's operating cash flow is negative, therefore debt is not well covered.

Interest Coverage: KWBT is unprofitable, therefore interest payments are not well covered by earnings.


Balance Sheet

Inventory Level: KWBT has a low level of unsold assets or inventory.

Debt Coverage by Assets: KWBT's debt is covered by short term assets (assets are 16.103740x debt).


Next Steps

Dividend

What is Kiwa Bio-Tech Products Group's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage2.3%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate KWBT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate KWBT's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if KWBT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if KWBT's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of KWBT's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Kiwa Bio-Tech Products Group's salary, the management and board of directors tenure and is there insider trading?

3.3yrs

Average management tenure


CEO

Yvonne Wang-Liu (41yo)

3.2yrs

Tenure

US$84,000

Compensation

Ms. Siuhung Wang-Liu, also known as Yvonne has been an Acting Chief Executive Officer and Acting President of Kiwa Bio-Tech Products Group Corporation since August 11, 2016. Ms. Wang-Liu has been the Chair ...


CEO Compensation Analysis

Compensation vs. Market: Yvonne's total compensation ($USD84.00K) is about average for companies of similar size in the US market ($USD509.77K).

Compensation vs Earnings: Yvonne's compensation has been consistent with company performance over the past year.


Management Age and Tenure

3.3yrs

Average Tenure

41yo

Average Age

Experienced Management: KWBT's management team is considered experienced (3.3 years average tenure).


Board Age and Tenure

4.3yrs

Average Tenure

41yo

Average Age

Experienced Board: KWBT's board of directors are considered experienced (4.3 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Qi Wang (53yo)

    VP of Technology & Director

    • Tenure: 12.3yrs
  • Yvonne Wang-Liu (41yo)

    Chairman

    • Tenure: 3.2yrs
    • Compensation: US$84.00k
  • Hon Man Yun (50yo)

    Chief Financial Officer

    • Tenure: 1.5yrs
    • Compensation: US$102.40k
  • Lucy Li (31yo)

    Secretary & Director

    • Tenure: 4.8yrs
  • Xiao Qiang Yu (41yo)

    Director

    • Tenure: 0.3yrs
    • Compensation: US$31.00k
  • Weijun Xu

    • Tenure: 0yrs

Board Members

  • Qi Wang (53yo)

    VP of Technology & Director

    • Tenure: 12.3yrs
  • Yvonne Wang-Liu (41yo)

    Chairman

    • Tenure: 3.2yrs
    • Compensation: US$84.00k
  • Lucy Li (31yo)

    Secretary & Director

    • Tenure: 4.8yrs
  • Xiao Qiang Yu (41yo)

    Director

    • Tenure: 0.3yrs
    • Compensation: US$31.00k

Company Information

Kiwa Bio-Tech Products Group Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Kiwa Bio-Tech Products Group Corporation
  • Ticker: KWBT
  • Exchange: OTCPK
  • Founded: 2002
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$3.045m
  • Shares outstanding: 20.30m
  • Website: https://www.kiwabiotech.com

Number of Employees


Location

  • Kiwa Bio-Tech Products Group Corporation
  • International Agriculture Innovation Hub
  • 9th Floor
  • Yangling
  • Shaanxi Province
  • 712100
  • China

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
KWBTOTCPK (Pink Sheets LLC)YesCommon StockUSUSDMar 2004

Biography

Kiwa Bio-Tech Products Group Corporation, through its subsidiaries, develops, manufactures, markets, and distributes bio-technological products for the agricultural market primarily in the People’s Republi ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/21 23:55
End of Day Share Price2019/10/21 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.